Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus

Overview

The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with Systemic Lupus Erythematosus (SLE)

Full Title of Study: “A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Four 12-week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects With Moderate to Severe Disease”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: May 2015

Interventions

  • Drug: Epratuzumab
    • 600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
  • Drug: Epratuzumab
    • 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
  • Drug: Placebo
    • Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles

Arms, Groups and Cohorts

  • Placebo Comparator: Placebo (Weekly infusion)
    • Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles
  • Experimental: Epratuzumab 600 mg per week
    • 600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
  • Experimental: Epratuzumab 1200 mg every other week
    • 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles

Clinical Trial Outcome Measures

Primary Measures

  • The Percent of Subjects Meeting Treatment Response Criteria at Week 48 According to a Combined Response Index
    • Time Frame: At Week 48
    • Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set. The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) – no worsening compared to study entry, physician’s global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.

Secondary Measures

  • The Percent of Subjects Meeting Treatment Response Criteria at Week 24 According to a Combined Response Index
    • Time Frame: At Week 24
    • Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set. The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) – no worsening compared to study entry, physician’s global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.
  • The Percent of Subjects Meeting Treatment Response Criteria at Week 12 According to a Combined Response Index
    • Time Frame: At Week 12
    • Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set. The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) – no worsening compared to study entry, physician’s global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.
  • The Percent of Subjects Meeting Treatment Response Criteria at Week 36 According to a Combined Response Index
    • Time Frame: At Week 36
    • Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set. The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) – no worsening compared to study entry, physician’s global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.
  • Change From Baseline in Daily Corticosteroid Dose at Week 24
    • Time Frame: At Week 24
    • Subjects with a missing corticosteroid dose at any visit for any reason are counted in the Dose Increased or Missing Data category for that visit.
  • Change From Baseline in Daily Corticosteroid Dose at Week 48
    • Time Frame: At Week 48
    • Subjects with a missing corticosteroid dose at any visit for any reason are counted in the Dose Increased or Missing Data category for that visit.

Participating in This Clinical Trial

Inclusion Criteria

  • Positive antinuclear antibodies (ANA) at Screening (Visit 1) – Current clinical diagnosis of Systemic Lupus Erythematosus (SLE) by American College of Rheumatology (ACR) criteria such that at least 4 of the 11 criteria are met – Active moderate to severe SLE activity as demonstrated by the British Isles Lupus Assessment Group Index (BILAG) – Active moderate to severe SLE disease as demonstrated by SLEDAI total score. – On stable SLE treatment regimen, including mandatory corticosteroids and immunosuppressants or antimalarials Exclusion Criteria:

  • Subjects who are breastfeeding, pregnant, or plan to become pregnant – Subjects with active, severe SLE disease activity which involves the renal system – Subjects with active, severe, neuropsychiatric SLE, defined as any neuropsychiatric element scoring BILAG level A disease. – Subjects with the evidence of an immunosuppressive state – Subjects who, in the opinion of the investigator, are at a particularly high risk of significant infection – History of malignant cancer, except the following treated cancers: cervical carcinoma in situ, basal cell carcinoma, or dermatological squamous cell carcinoma. – Subjects receiving any live vaccination within the 8 weeks prior to screening (Visit 1). – Subjects with history of infections, including but not limited to concurrent acute or chronic viral hepatitis B or C – Subjects with substance abuse or dependence or other relevant concurrent medical condition – Subjects with history of thromboembolic events within 1 year of screening Visit. – Subjects with significant hematologic abnormalities – Subject has received treatment with other anti- B cell antibodies within 12 months prior to screening (visit 1) – Subject use of oral anticoagulant (not including) nonsteroidal anti-inflammatory drugs (NSAIDs) within 12 weeks prior to screening (Visit 1) – Subject has previously participated in this study or has previously received epratuzumab treatment.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • UCB Pharma
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • UCb Clinical Trial Call Center, Study Director, +1 877 822 9493 (UCB)

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.